Drug Profile
Research programme: musculoskeletal therapeutics - Enobia Pharma
Alternative Names: MH-2-64C; Osteocrin; PHEX inhibitor 1; PHEX inhibitor 2Latest Information Update: 22 Feb 2010
Price :
$50
*
At a glance
- Originator Enobia Pharma
- Class Small molecules
- Mechanism of Action Endopeptidase inhibitors; Metalloprotease inhibitors; Neprilysin inhibitors; Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bone disorders; Cartilage disorders; Fracture; Osteodystrophy; Osteoporosis; Periodontal disorders
Most Recent Events
- 22 Feb 2010 Discontinued - Preclinical for Bone disorders in Canada (PO)
- 22 Feb 2010 Discontinued - Preclinical for Cartilage disorders in Canada (PO)
- 22 Feb 2010 Discontinued - Preclinical for Fracture in Canada (PO)